Study on efficacy and safety as well as on the changes in blood purine compounds by the treatment of patients with amyotrophic lateral sclerosis with febuxostat and inosine in combination.

Study on efficacy and safety as well as on the changes in blood purine compounds by the treatment of patients with amyotrophic lateral sclerosis with febuxostat and inosine in combination. - Effect of febuxostat and inosine on amyotrophic lateral sclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029308

Enrollment

Registered

2018-09-30

Start date

2017-07-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis

Interventions

Febuxostat 20 mg, Inosine 500 mg, twice a day for 14 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Japanese patients with 20 to 80 years of age who are the outpatients of Teikyo University Hospital 2. Patients who have been diagnosed as amyotrophic lateral sclerosis

Exclusion criteria

Exclusion criteria: 1. Subject who has or had hypersensitivity, idiosyncracy (allergy) to drug. 2. Subjects taking azathioprine or mercaptopurine 3. Subject who has or had renal function disorder. 4. Subject with a history of gout, hyperuricemia or urolithiasis. 5. Patients who changed therapeutic drugs and treatment methods within 1 month before administration of test drugs 6. Subject who was judged not to be appropriate by the principal investigator or sub investigators by other reasons.

Design outcomes

Primary

Measure	Time frame
Difference of ALSFRS-R between before and after the treatment	—

Countries

Japan

Contacts

Public ContactFumiaki Saito

Teikyo University Department of neurology, Faculty of Medicine

f-saito@med.teikyo-u.ac.jp03-3964-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026